<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00487162</url>
  </required_header>
  <id_info>
    <org_study_id>0120070093</org_study_id>
    <nct_id>NCT00487162</nct_id>
  </id_info>
  <brief_title>The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality</brief_title>
  <official_title>The Association Between Peri-Operative Hyperglycemia and Major Morbidity and Mortality</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Medicine and Dentistry of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Surgery induces a stress effect on the body partially through a catabolic energy state. In&#xD;
      turn, glucose levels may rise to levels which have been associated with major morbidity&#xD;
      (Golden, 1999) and mortality (Ouattara, 2005). An increasing body of evidence suggests that&#xD;
      intensive insulin therapy for tight control of blood glucose levels in certain surgical and&#xD;
      critical care patient populations may improve mortality and selected morbidity outcomes when&#xD;
      compared to those patients receiving conventional insulin therapy and blood glucose&#xD;
      management. More specifically, poor intra-operative blood glucose control is associated with&#xD;
      worse outcome after cardiac surgery. Intensive insulin therapy with tight blood glucose&#xD;
      control in surgical patients while in the ICU may reduce morbidity and mortality. Such&#xD;
      outcome improvements would clearly provide benefits to patients, providers and payers. To&#xD;
      date, there is scant research examining whether intensive insulin therapy for tight control&#xD;
      of blood glucose in the perioperative period can alter outcomes for the non cardiac surgery&#xD;
      population. The purpose of this study is to determine whether intensive insulin therapy for&#xD;
      tight control of blood glucose in the perioperative period in non cardiac major surgery&#xD;
      patients is associated with altered morbidity and mortality rates.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intensive insulin therapy to control blood glucose levels reduces morbidity and mortality in&#xD;
      intensive care unit patients and in cardiac surgical patients but its role in patients&#xD;
      undergoing non-emergent non-cardiac surgery is unknown. Benefits of glucose control may&#xD;
      result from prevention of immune system dysfunction, reduction in systemic inflammation, and&#xD;
      protection of endothelium and mitochondrial structure and function, all of which are known to&#xD;
      be altered by high stress states such as that induced by surgical procedures.&#xD;
&#xD;
      In a prospective, randomized, controlled study of adult patients admitted to our operating&#xD;
      suite for non-emergent non-cardiac surgery, we propose to correlate in-hospital morbidity and&#xD;
      mortality with blood glucose levels of patients who are expected to have moderate to high&#xD;
      levels of physiologic stress as a result of their pre-existing medical conditions or as a&#xD;
      result of the proposed surgical procedure. Specifically, patients who are deemed to be&#xD;
      American Society of Anesthesiologists Risk Classification 1-3 or higher, or patients&#xD;
      undergoing intermediate and high risk procedures shall be considered to have moderate to high&#xD;
      physiologic stress.&#xD;
&#xD;
      Determination of intermediate / high risk procedures shall be according to the American&#xD;
      College of Cardiology / American Heart Association 2002 Guidelines for Perioperative&#xD;
      Cardiovascular Evaluation for Noncardiac Surgery as outlined in Table 1.&#xD;
&#xD;
      Table 1. Cardiac Event Risk Stratification for Noncardiac Surgical Procedures High (Reported&#xD;
      cardiac risk often &gt;5%)&#xD;
&#xD;
        -  Emergent major operations, particularly in the elderly&#xD;
&#xD;
        -  Aortic and other major vascular surgery&#xD;
&#xD;
        -  Peripheral vascular surgery&#xD;
&#xD;
        -  Anticipated prolonged surgical procedures associated with large fluid shifts and/or&#xD;
           blood loss Combined incidence of cardiac death and nonfatal myocardial infarction.&#xD;
           Further preoperative cardiac testing is not generally required. Intermediate (Reported&#xD;
           cardiac risk generally &lt;5%)&#xD;
&#xD;
        -  Intraperitoneal and intrathoracic surgery&#xD;
&#xD;
        -  Carotid endarterectomy surgery&#xD;
&#xD;
        -  Head and neck surgery&#xD;
&#xD;
        -  Orthopedic surgery&#xD;
&#xD;
        -  Prostate surgery Low (Reported cardiac risk generally &lt;1%):&#xD;
&#xD;
        -  Endoscopic procedures&#xD;
&#xD;
        -  Superficial procedures&#xD;
&#xD;
        -  Cataract surgery&#xD;
&#xD;
        -  Breast surgery&#xD;
&#xD;
      Prior to entering the operating suite for surgery, patients will be randomly assigned to&#xD;
      receive either intensive insulin treatment or conventional insulin treatment. Treatment&#xD;
      assignment will be performed using sealed envelopes, and patients stratified according to&#xD;
      Table 2.&#xD;
&#xD;
      TABLE 2. Baseline Characteristics of Patients. Variable Intention to Treat Group P Value Male&#xD;
      sex (%) Age (Years) Type of Surgery&#xD;
&#xD;
        -  Intracranial (%)&#xD;
&#xD;
        -  Head &amp; Neck (%)&#xD;
&#xD;
        -  Thoracic (%)&#xD;
&#xD;
        -  Vascular (%)&#xD;
&#xD;
        -  Gastrointestinal (%)&#xD;
&#xD;
        -  Urologic (%)&#xD;
&#xD;
        -  Orthopedic (%)&#xD;
&#xD;
        -  Gynecologic (%)&#xD;
&#xD;
        -  Myocutaneous (%) History of Cancer (%) History of Organ Failure before Surgery (%) Organ&#xD;
           Failure After Surgery (%) History of Diabetes (%)&#xD;
&#xD;
        -  Treated with insulin&#xD;
&#xD;
        -  Treated with oral diabetic agent, diet or both&#xD;
&#xD;
      Inclusion criteria:&#xD;
&#xD;
        -  Patients scheduled for non emergent surgery under either general or regional anesthesia&#xD;
           deemed to have moderate to high physiologic stress&#xD;
&#xD;
        -  Male and female subjects over the age of 18 with or without a diagnosis of diabetes&#xD;
           mellitus&#xD;
&#xD;
        -  Patients must be able to provide informed consent&#xD;
&#xD;
      Exclusion criteria:&#xD;
&#xD;
        -  Cognitively impaired&#xD;
&#xD;
        -  Non-English or Spanish speaking with no relative present who is fluent in reading and&#xD;
           comprehending English or Spanish.&#xD;
&#xD;
        -  Female patients of child bearing age who have a positive pregnancy test on admission.&#xD;
&#xD;
      In all patients, whole blood hemoglobin A1C and glucose levels will be drawn prior to&#xD;
      induction of anesthesia. Additional whole blood glucose levels will be drawn at the time of&#xD;
      induction of anesthesia, at skin incision, hourly throughout the operation, at emergence from&#xD;
      anesthesia, every hour up to three hours after the completion of surgery, and then once per&#xD;
      day until the patient is discharged from the hospital.&#xD;
&#xD;
      In the intensive treatment group, continuous insulin infusion (50 IU of Novolin R [Novo&#xD;
      Nordisk]) in 50mL of 0.9% saline via infusion pump will be started when the blood glucose&#xD;
      level exceeds 110 mg/dL and will be adjusted to maintain the blood glucose level between 80&#xD;
      and 110 mg/dL. Adjustments will be made according to the University Hospital's ICU Adult&#xD;
      Insulin Infusion Protocol. When the blood glucose level falls below 80 mg/dL, the insulin&#xD;
      infusion will be tapered and discontinued. For patients going to the ICU after surgery,&#xD;
      insulin infusions will be continued according to the University Hospital's ICU Adult Insulin&#xD;
      Infusion Protocol under the direction of the ICU staff. For patients not being to the ICU&#xD;
      after surgery, insulin infusions will be tapered to off after the final hourly blood glucose&#xD;
      determination at three hours after the completion of surgery. The University Hospital's Blood&#xD;
      Glucose Management Order Set for Medical and Surgical Patients will then be adopted for&#xD;
      continued glucose management.&#xD;
&#xD;
      In the conventional treatment group, continuous insulin infusion will be started when the&#xD;
      blood glucose level exceeds 200 mg/dL and will be adjusted to maintain the blood glucose&#xD;
      level between 180 and 200 mg/dL. Adjustments will be made according to a modified ICU Adult&#xD;
      Insulin Infusion Protocol. When the blood glucose level falls below 180mg/dL, the insulin&#xD;
      infusion will be tapered and discontinued. For patients transferred to an ICU after surgery,&#xD;
      insulin infusions will be continued according to the University Hospital's ICU Adult Insulin&#xD;
      Infusion Protocol under the direction of the ICU staff. For patients not being transferred to&#xD;
      an ICU after surgery, insulin infusions will be tapered to off after the final hourly blood&#xD;
      glucose determination at three hours after the completion of surgery. The University&#xD;
      Hospital's Blood Glucose Management Order Set for Medical and Surgical Patients will then be&#xD;
      adopted for continued glucose management.&#xD;
&#xD;
      How will the study be analyzed?&#xD;
&#xD;
      At baseline, data on demographic and clinical characteristics of the patients (see Table 1)&#xD;
      will be obtained. Blood will be systematically sampled and whole blood glucose levels&#xD;
      determined as described above. All blood glucose values will be tabulated from baseline&#xD;
      through end of study.&#xD;
&#xD;
      A research associate blinded to the treatment groups will determine morbidity and mortality&#xD;
      by reviewing the patient's medical record upon discharge from the hospital and recording the&#xD;
      occurrence of morbidity and mortality by the following criteria:&#xD;
&#xD;
        1. Post-operative surgical wound infection - a clinical condition requiring antibiotic&#xD;
           treatment beyond the UH Surgical Infection Prevention (SIP) protocol and / or subsequent&#xD;
           wound drainage / debridement&#xD;
&#xD;
        2. Systemic infection - presence of bacteremia or prolonged (i.e. greater than 10 days) use&#xD;
           of antibiotics&#xD;
&#xD;
        3. Myocardial Injury - postoperative EKG changes that reveal new Q waves or S-T segment&#xD;
           elevations greater than 1mm in any lead(s) or serum troponin levels that exceedâ€¦.&#xD;
&#xD;
        4. Malignant arrhythmia - asystole, ventricular tachycardia or fibrillation requiring&#xD;
           cardiopulmonary resuscitation, antiarrhythmia therapy, or defibrillator implantation&#xD;
&#xD;
        5. Respiratory Injury - mechanical ventilation for more than 48 hours, reintubation, or&#xD;
           planned tracheostomy&#xD;
&#xD;
        6. Neurological Injury - focal brain injury with permanent functional deficit, irreversible&#xD;
           encephalopathy&#xD;
&#xD;
        7. Renal Injury - a level of serum creatinine twice that present on admission to the&#xD;
           hospital or acute renal failure requiring dialysis&#xD;
&#xD;
        8. Hepatic Injury - bilirubin level of &gt;3mg per deciliter&#xD;
&#xD;
        9. Venous Thromboembolism - deposition of thrombus in peripheral or central veins as&#xD;
           determined by Doppler ultrasonography, angiography or computed tomography.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    potential harm of insulin infusion outweights the benefit.&#xD;
  </why_stopped>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound Infection</measure>
    <time_frame>7-10 days post op</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemodynamic Instability</measure>
    <time_frame>0-48 hours post op</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Hyperglycemia</condition>
  <arm_group>
    <arm_group_label>intensive glycemic control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In the intensive treatment group, continuous insulin infusion (50 IU of Novolin R [Novo Nordisk]) in 50ml of 0.9% saline via infusion pump will be started when the blood glucose level exceeds 110 mg / dL on two consecutive samples and will be adjusted to maintain the blood glucose level between 80 and 110 mg / dL. If the glucose level falls below 80 mg / dL, the insulin infusion will be tapered and discontinued.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional glycemic control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this group if the subject's blood glucose level should exceed 200 mg/dL the subject will be treated with a continuous insulin infusion to maintain blood glucose levels between 180-200mg/dL</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>intensive glycemic control</intervention_name>
    <description>intravenous insulin titrated every 30 minutes to serum glycemic level of 80-100mg/dl</description>
    <arm_group_label>intensive glycemic control</arm_group_label>
    <other_name>Novo Regular Insulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>conventional glycemic control</intervention_name>
    <description>Novo regular insulin administered when glucose level exceeded 200 mg/dl and titrated to maintain level between 180-200 mg/dl</description>
    <arm_group_label>conventional glycemic control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients scheduled for non emergent surgery under either general or regional&#xD;
             anesthesia deemed to have moderate to high physiologic stress&#xD;
&#xD;
          -  Male and female subjects over the age of 18 with or without a diagnosis of diabetes&#xD;
             mellitus&#xD;
&#xD;
          -  Patients must be able to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cognitively impaired&#xD;
&#xD;
          -  Non-English or Spanish speaking with no relative present who is fluent in reading and&#xD;
             comprehending English or Spanish.&#xD;
&#xD;
          -  Female patients of child bearing age who have a positive pregnancy test on admission.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J Jeffery Freda, MD, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers, The State University of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001 Nov 8;345(19):1359-67.</citation>
    <PMID>11794168</PMID>
  </reference>
  <reference>
    <citation>Furnary AP, Gao G, Grunkemeier GL, Wu Y, Zerr KJ, Bookin SO, Floten HS, Starr A. Continuous insulin infusion reduces mortality in patients with diabetes undergoing coronary artery bypass grafting. J Thorac Cardiovasc Surg. 2003 May;125(5):1007-21.</citation>
    <PMID>12771873</PMID>
  </reference>
  <reference>
    <citation>Ouattara A, Lecomte P, Le Manach Y, Landi M, Jacqueminet S, Platonov I, Bonnet N, Riou B, Coriat P. Poor intraoperative blood glucose control is associated with a worsened hospital outcome after cardiac surgery in diabetic patients. Anesthesiology. 2005 Oct;103(4):687-94.</citation>
    <PMID>16192760</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>June 13, 2007</study_first_submitted>
  <study_first_submitted_qc>June 13, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2007</study_first_posted>
  <results_first_submitted>December 3, 2010</results_first_submitted>
  <results_first_submitted_qc>February 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 3, 2014</results_first_posted>
  <last_update_submitted>October 4, 2016</last_update_submitted>
  <last_update_submitted_qc>October 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>glycemic control, diabetes, obesity, comorbidities</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>enrollment period 6/07-3/09. potential subjects were recruited from the pre-operative admission unit and were screened if there ages were 18-90,undergoing general anesthesia for surgical procedures greater than 2 hours.</recruitment_details>
      <pre_assignment_details>Subjects were randomized to a specific study arm based on a computer generated randomization table. 49 participants are included in the baseline characteristic module because although 56 signed consent, some subjects withdrew the consent prior to study procedures and several withdrawn by attending anesthesiologist.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Conventional Glycemic Control</title>
          <description>Subjects randomized to this study arm had their glucose levels monitored hourly and if the result was greater than 200mg/dL their anesthesia care provider was notified. The subject was treated as to thie care provider discretion.</description>
        </group>
        <group group_id="P2">
          <title>Intensive Glycemic Control</title>
          <description>In the intensive treatment group, continuous insulin infusion (50 IU of Novolin R [Novo Nordisk]) in 50ml of 0.9% saline via infusion pump will be started when the blood glucose level exceeds 110 mg / dL on two consecutive samples and will be adjusted to maintain the blood glucose level between 80 and 110 mg / dL. Adjustments will be made according to the University Hospital's ICU Adult Insulin Infusion Protocol - modified 10/1/07 (Appendix A). When the blood glucose level falls below 80 mg / dL, the insulin infusion will be tapered and discontinued. For patients going to the ICU after surgery, insulin infusions will be continued according to the University Hospital's ICU Adult Insulin Infusion Protocol under the direction of the ICU staff. For patients not being to the ICU after surgery, insulin infusions will be tapered to off after the final hourly blood glucose determination at three hours after the completion of surgery.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>males and females between the ages of 18 and 89.</population>
      <group_list>
        <group group_id="B1">
          <title>Conventional Glycemic Control</title>
          <description>Subjects randomized to this study arm had their glucose levels monitored hourly and if the result was greater than 200 mg/dL their anesthesia care provider was notified. The subject was treated as to their care provider discretion.</description>
        </group>
        <group group_id="B2">
          <title>Intensive Glycemic Control</title>
          <description>In this treatment group, continuous insulin infusion (50 IU of Novolin R [Novo Nordisk]) in 50mL of 0.9% saline via infusion pump will be started when the blood glucose level exceeds 110 mg/dL and will be adjusted to maintain the blood glucose level between 80 and 110 mg/dL.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Wound Infection</title>
        <time_frame>7-10 days post op</time_frame>
        <population>no analysis was done as the study was terminated due to patient safety concerns</population>
        <group_list>
          <group group_id="O1">
            <title>Strict Glycemic Control</title>
            <description>strict glycemic control: intravenous insulin titrated every 30 minutes to serum glycemic level of 80-100mg/dl</description>
          </group>
          <group group_id="O2">
            <title>Conventional Glycemic Control</title>
            <description>conventional glycemic control: Novo regular insulin administered when glucose level exceeded 200 mg/dl and titrated to maintain level between 180-200 mg/dl</description>
          </group>
        </group_list>
        <measure>
          <title>Wound Infection</title>
          <population>no analysis was done as the study was terminated due to patient safety concerns</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemodynamic Instability</title>
        <time_frame>0-48 hours post op</time_frame>
        <population>no analysis was done as the study was terminated due to patient safety concerns</population>
        <group_list>
          <group group_id="O1">
            <title>Strict Glycemic Control</title>
            <description>strict glycemic control: intravenous insulin titrated every 30 minutes to serum glycemic level of 80-100mg/dl</description>
          </group>
          <group group_id="O2">
            <title>Conventional Glycemic Control</title>
            <description>conventional glycemic control: Novo regular insulin administered when glucose level exceeded 200 mg/dl and titrated to maintain level between 180-200 mg/dl</description>
          </group>
        </group_list>
        <measure>
          <title>Hemodynamic Instability</title>
          <population>no analysis was done as the study was terminated due to patient safety concerns</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Conventional Glycemic Control</title>
          <description>Subjects randomized to this study arm had their glucose levels monitored hourly and if the result was greater than 200mg/dL their anesthesia care provider was notified. The subject was treated as to their care provider discretion.</description>
        </group>
        <group group_id="E2">
          <title>Intensive Glycemic Control</title>
          <description>Subjects randomized to this group had glucose levels monitored hourly and when &gt;110mg/dL an insulin drip was initiated to maintain glucose levels between 80-110</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>hypoglycemia</sub_title>
                <description>subject's serum blood glucose level dropped to &lt;60. Insulin discontinued</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was terminated. No final conclusion drawn. A sentinel article was published in Feb 2009 issue of Anesthesiology which questioned the safety of intense insulin therapy/strict glycemic control.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>J. Jeffrey Freda, MD, MBA</name_or_title>
      <organization>UMDNJ-NJMS</organization>
      <phone>973 972-5007</phone>
      <email>jjfreda@umdnj.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

